Biotech Values

[DewDiligence]

ITMN—What I found most noteworthy about the MS webcast was Welch’s all but conceding that ritonavir boosting precludes ITMN-191’s ever being combined with a non-nuke or an NS5A inhibitor. Unlike nukes, these classes of HCV drugs generally use the CYP450 elimination pathway.